While various classifications of GBMs and/or their constitutive bulk and stem tumor cells have been reported, with some associating with patient survival (Neftel et al., 2019; Patel et al., 2014; Cancer Genome Atlas Research Network et al., 2010; Wang et al., 2017; Yin et al., 2019; Zuo et al., 2019), molecular signatures in adult GBM stratifying the poorer prognosis IDH wild-type patients by survival are lacking. Here, IDH2 is linked to glioblastoma.